Biotest Skyrockets Q1 2024 Sales by 83.6% to a Whopping €215.2 Million

• Biotest AG increased sales by 83.6% to Euro 215.2 million in the first quarter of 2024.
• Product sales increased by 17.7% to Euro 138.0 million, and EBIT increased to Euro 52.8 million.
• The new intravenous immunoglobulin Yimmugo had a positive impact with an increase in sales of € 7.5 million to € 11.1 million.
• Biotest Group's earnings after taxes improved to € 29.5 million in the first quarter of 2024 after € -20.4 million in the same quarter of the previous year.
• Biotest is expanding its own plasma collection network in Europe and operated 37 plasma collection centres in Germany, Hungary and the Czech Republic by the end of the first quarter of 2024.
• Biotest is seeking approval for Yimmugo in the US market, and has completed Phase III trials for the use of Fibrinogen concentrate in the indications of congenital and acquired fibrinogen deficiency.

The next important date, Publication of Quarterly Report (Cut-off date Q1), at Biotest is on 07.05.2024.

The price of Biotest at the time of the news was 27,90EUR and was down -0,36 % compared with the previous day.

Biotest

0,00 %

-0,36 %

-4,15 %

-1,77 %

-11,22 %

-4,81 %

+29,44 %

-1,07 %

+385,71 %

ISIN:DE0005227235WKN:522723

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max